HK1211297A1 - Binding proteins comprising at least two repeat domains against her2 her2 - Google Patents

Binding proteins comprising at least two repeat domains against her2 her2

Info

Publication number
HK1211297A1
HK1211297A1 HK15110090.1A HK15110090A HK1211297A1 HK 1211297 A1 HK1211297 A1 HK 1211297A1 HK 15110090 A HK15110090 A HK 15110090A HK 1211297 A1 HK1211297 A1 HK 1211297A1
Authority
HK
Hong Kong
Prior art keywords
her2
binding proteins
repeat domains
domains against
against her2
Prior art date
Application number
HK15110090.1A
Other languages
English (en)
Chinese (zh)
Inventor
烏爾麗克‧菲德勒
伊格納西奧‧多拉多
海克‧施特羅貝爾
Original Assignee
Molecular Partners Ag
14 Ch 8952
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag, 14 Ch 8952 filed Critical Molecular Partners Ag
Publication of HK1211297A1 publication Critical patent/HK1211297A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)
HK15110090.1A 2012-11-30 2015-10-15 Binding proteins comprising at least two repeat domains against her2 her2 HK1211297A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195156.0A EP2738180A1 (en) 2012-11-30 2012-11-30 Binding proteins comprising at least two binding domains against HER2.
PCT/EP2013/075290 WO2014083208A1 (en) 2012-11-30 2013-12-02 Binding proteins comprising at least two repeat domains against her2

Publications (1)

Publication Number Publication Date
HK1211297A1 true HK1211297A1 (en) 2016-05-20

Family

ID=47257683

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110090.1A HK1211297A1 (en) 2012-11-30 2015-10-15 Binding proteins comprising at least two repeat domains against her2 her2

Country Status (11)

Country Link
US (1) US10370414B2 (ru)
EP (2) EP2738180A1 (ru)
JP (1) JP6410724B2 (ru)
KR (1) KR102290592B1 (ru)
CN (1) CN104918959A (ru)
AU (2) AU2013351096C9 (ru)
CA (1) CA2892747C (ru)
HK (1) HK1211297A1 (ru)
MX (1) MX366223B (ru)
RU (1) RU2664464C9 (ru)
WO (1) WO2014083208A1 (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
EP2643349B1 (en) * 2010-11-26 2019-09-04 Molecular Partners AG Designed repeat proteins binding to serum albumin
CA2883264A1 (en) * 2012-10-15 2014-04-24 Universitat Zurich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
AU2014357292B2 (en) 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2
US10858405B2 (en) 2015-02-06 2020-12-08 Navigo Proteins Gmbh EGFR binding proteins
WO2016156596A1 (en) * 2015-04-02 2016-10-06 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
US10808042B2 (en) 2015-07-16 2020-10-20 Navigo Proteins Gmbh Immunoglobulin-binding proteins and their use in affinity purification
DK3325514T3 (da) * 2015-07-20 2019-12-16 Navigo Proteins Gmbh Her2-bindende proteiner baseret på di-ubiquitin-muteiner
US10584152B2 (en) 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
WO2017191252A1 (en) 2016-05-04 2017-11-09 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
RU2627215C1 (ru) * 2016-05-24 2017-08-03 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского" Рекомбинантный таргетный токсин, специфичный к клеткам, экспрессирующим рецептор her2
CA3030208A1 (en) 2016-08-11 2018-02-15 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin binding proteins
MY196882A (en) * 2016-09-22 2023-05-08 Molecular Partners Ag Recombinant binding proteins and their use
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
CN114222757A (zh) * 2019-06-04 2022-03-22 分子伴侣公司 重组4-1bb结合蛋白及其用途
KR20220016942A (ko) 2019-06-04 2022-02-10 몰리큘라 파트너스 아게 재조합 fap 결합 단백질 및 이의 용도
AR119080A1 (es) 2019-06-04 2021-11-24 Molecular Partners Ag Proteínas multiespecíficas
JP2022535106A (ja) * 2019-06-04 2022-08-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 改善された安定性を有する設計されたアンキリン反復ドメイン
CN114929730A (zh) * 2019-12-11 2022-08-19 分子合作伙伴股份公司 重组肽-mhc复合物结合蛋白及其生成和用途
CN115916815A (zh) 2020-05-06 2023-04-04 分子合作伙伴股份公司 新型锚蛋白重复结合蛋白及其用途
CN115768786A (zh) 2020-05-14 2023-03-07 分子合作伙伴股份公司 多特异性蛋白质
WO2022130300A1 (en) 2020-12-16 2022-06-23 Molecular Partners Ag Novel slow-release prodrugs
AU2022233791A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd123 engagers
JP2024508969A (ja) 2021-03-09 2024-02-28 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規のDARPinに基づくCD33エンゲージャ
JP2024509890A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト プロテアーゼ切断可能なプロドラッグ
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91501A (en) 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
ATE321849T1 (de) 1997-04-23 2006-04-15 Univ Zuerich Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
ATE354675T1 (de) 1998-12-02 2007-03-15 Adnexus Therapeutics Inc Dna-protein fusionen sowie anwendungen derselben
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
AU2005249396B2 (en) * 2004-05-05 2011-10-20 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
ES2521140T3 (es) * 2004-07-22 2014-11-12 Genentech, Inc. Composición de anticuerpos de HER2
ATE448305T1 (de) 2005-07-08 2009-11-15 Univ Zuerich Phagen-display mittels cotranslationaler translokation von fusionspolypeptiden
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
DK2173890T3 (da) 2007-06-21 2011-06-27 Univ Muenchen Tech Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
US20110053865A1 (en) 2007-11-27 2011-03-03 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
ES2836948T3 (es) 2008-11-03 2021-06-28 Molecular Partners Ag Proteínas de unión que inhiben la interacción del receptor de VEGF-A
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
EP2643349B1 (en) 2010-11-26 2019-09-04 Molecular Partners AG Designed repeat proteins binding to serum albumin
BR112013027766A2 (pt) 2011-04-29 2016-11-29 Janssen Biotech Inc proteinas de repetição de ligação de il4/il13 e usos
WO2012162418A1 (en) * 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heterodimeric targeting ligands
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
CA2883264A1 (en) 2012-10-15 2014-04-24 Universitat Zurich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor

Also Published As

Publication number Publication date
AU2013351096C1 (en) 2018-11-08
WO2014083208A8 (en) 2014-10-30
EP2925784B1 (en) 2021-02-17
AU2018256592A1 (en) 2018-11-22
AU2013351096C9 (en) 2019-01-31
CN104918959A (zh) 2015-09-16
CA2892747C (en) 2022-07-19
KR20150091138A (ko) 2015-08-07
US20150299265A1 (en) 2015-10-22
BR112015012436A2 (pt) 2017-09-12
JP2015537044A (ja) 2015-12-24
MX2015006548A (es) 2015-10-15
RU2015120663A (ru) 2017-01-10
JP6410724B2 (ja) 2018-10-24
WO2014083208A1 (en) 2014-06-05
AU2013351096A1 (en) 2015-07-09
CA2892747A1 (en) 2014-06-05
MX366223B (es) 2019-07-03
EP2925784A1 (en) 2015-10-07
KR102290592B1 (ko) 2021-08-19
WO2014083208A9 (en) 2014-12-24
EP2738180A1 (en) 2014-06-04
US10370414B2 (en) 2019-08-06
RU2664464C9 (ru) 2018-12-19
RU2664464C2 (ru) 2018-08-17
AU2013351096B2 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
HK1211297A1 (en) Binding proteins comprising at least two repeat domains against her2 her2
IL282226A (en) ST2 antigen-binding proteins
HK1216894A1 (zh) 多價結合蛋白組合物
IL240838A0 (en) Anti-3–lag binding proteins
HK1212711A1 (zh) 抗原結合蛋白
IL254652B (en) Unnatural albumin binding sites
IL240915A0 (en) Dual-specific binding proteins directed against tnfɑ
HK1214167A1 (zh) 結合的抗感染結合蛋白
HK1204948A1 (en) Radiation-sterilization-resistant protein composition
GB201418608D0 (en) Peridinin-chlorophyll binding proteins
GB201213672D0 (en) Protein
GB201200563D0 (en) Binding molecule
EP2817324A4 (en) NEMO BOND DOMAIN FUSION PROTEINS
GB201215901D0 (en) Protein modification
GB201200743D0 (en) Protein bridges